1. This is a phase I trial to assess the safety and PK of the drug. In general, a placebo control is not needed for this kind of study that aims to determine safety and PK. Having a control group in this study may lead to unnecessary exposure to invasive procedure among control participants. What is the rationale to measure PK and collect serial rectal specimens among the control group? Although, the PI stated that having a control group will help to reduce observation and measurement bias, due to a small sample size like in this phase I trial, the differences between groups may not be detected anyway.
2. Pleaseprovidemore information on the background and rationale, including details of the drug used in thisstudy, as well as previous studies regarding this drug.
3. Please providemore information about the toxicology and pharmacology of the drug in the Research proposal submission form (FTM ECF-019-05).
4. The protocol stated that NHSO and SSO cover care for injuries incurred from study procedures. The committee resolved that the study should take full responsibility inproviding care to participants for events related to the study, and not only provide immediate care and then refer to hospitals under the patient’shealth coverage. Please revise this part and specify clearly which hospital they must to go when they are injured from study procedures.